Evidence map›Paper›PMID 38485849›Full record

ArticleThe AAPS journal2024

Science- and Risk-Based Stability Strategies to Support Product Lifecycle Changes.

Lori McCaig, Steven Nowak, Alexander Abbott, Jenny Carhart, Megan E McMahon, Elke Debie, Hanlin Li, Francis Maina, Andrea J Ji, Mingkun Fu and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Lori McCaigPfizer Inc, 21823 30Th Drive SE, Bothell, Washington, 98021, USA.
Steven NowakAbbVie, 1 N Waukegan Rd. Bldg. AP50; Dept PA71, North Chicago, Illinois, 60064, USA. steven.a.nowak@abbvie.com.
Alexander AbbottOral Product Development, Pharmaceutical Technology & Development, Operations, AstraZeneca, Silk Road Business Park, Macclesfield, Cheshire, SK10 2NA, UK.
Jenny CarhartTakeda Development Center Americas, Inc. 95 Hayden Ave, Lexington, Massachusetts, 02421, USA.
Megan E McMahonPfizer Inc, Eastern Point Road, Groton, Connecticut, 06340, USA.
Elke DebieJanssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium.
Hanlin LiVertex Pharmaceuticals, 50 Northern Avenue, Boston, Massachusetts, 02210, USA.
Francis MainaAbbVie, 1401 Sheridan Road, North Chicago, Illinois, 60064, USA.
Andrea J JiGenentech Inc, 1 DNA Way, South San Francisco, California, 94080, USA.
Mingkun FuSumitomo Pharma America, 84 Waterford Drive, Marlborough, Massachusetts, 01752, USA.
Yan WuMerck & Co, 2000 Galloping Hill Road, Kenilworth, New Jersey, 07033, USA.
Andrew LennardAmgen Ltd, 4, Uxbridge Business Park, Sanderson Road, Uxbridge, UB8 1DH, UK.
Tony MazzeoBristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey, 08903, USA.
Chad WolfeEli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana, 46285, USA.
Robert TimpanoPfizer Inc, Eastern Point Road, Groton, Connecticut, 06340, USA.
Yelizaveta BabayanEli Lilly & Company, Lilly Corporate Center, Indianapolis, Indiana, 46285, USA.
Lars GruenigCSL Behring, CSL Behring AG, Wankdorfstrasse 10, CH-3014, Bern, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ICH Q12 asserts that science- and risk-based approaches are applicable to stability studies supporting Chemistry, Manufacturing and Controls (CMC) post-approval changes (PAC) to enable more timely implementation; however, no guidance or specific examples are provided to demonstrate how prior knowledge of the product can inform the risk assessment for the proposed change(s). Ten diverse case studies are presented in this manuscript to demonstrate how science- and risk-based stability strategies were used to support drug substance and product CMC PAC and lifecycle management activities. The accumulated stability knowledge held by original manufacturers of marketed products is substantial, and different elements of this knowledge base were used to assess the risks and impact of the proposed changes for confident change management. This paper provides ways to leverage science- and risk-based stability strategies as part of the post-approval change-management risk-mitigation strategy, which may enable a reduced stability data commitment and/or a reduced reporting category for change implementation.

Indexed as

Risk ManagementRisk Assessmentaccelerated predictive stabilityICH Q12 product lifecyclepost-approval changescience- and risk-based stabilitystability risk assessment strategies

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.